Beam Therapeutics Inc. (BEAM)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XMEX 
Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript
Beam Therapeutics Inc (NASDAQ:BEAM ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Holly Manning - Vice President of Investor Relations & External Communications John Evans - Chief Executive Officer Giuseppe Ciaramella - President Amy Simon - Chief Medical Officer Conference Call Participants Gena Wang - Barclays Dae Gon Ha - Stifel Eric Joseph - JPMorgan Kostas Biliouris - BMO Capital Markets Samantha Semenkow - Citi Sami Corwin - William Blair Luca Issi - RBC Capital Michael Yee - Jefferies Rick Bienkowski - Cantor Fitzgerald Mani Foroohar - Leerink Partners Operator Good morning, and welcome to the Beam Therapeutics Conference Call. At this time, all participants are in a listen-only mode.
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.22 per share a year ago.
Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report?
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?
3 Gene Editing Stocks with Potential to Transform Medicine
Gene editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks. It could help treat the 7,000 diseases caused by genetic disorders, most of which occur with gene mutation.
Beam Therapeutics (BEAM) Q2 Earnings Beat, Revenues Miss
Beam Therapeutics (BEAM) reports mixed second-quarter results. The company remains focused on pipeline development.
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.08 per share a year ago.
Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?
Beam Therapeutics (BEAM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40
Speculators seeking a big pop over the next few months should consider a high-risk, high-reward position in Beam Therapeutics (NASDAQ: BEAM ). According to its public profile, Beam specializes in precision genetic medicines, which is a growing and viable market.
3 Gene Editing Stocks Shaping the Future of Medicine
Gene editing stocks represent one of the biggest investing trends in biopharma in recent years. The gene editing field employs advanced technologies to edit the DNA of different organisms, thereby opening up possibilities for transformative treatment options.
Beam Therapeutics' (BEAM) CFO to Step Down, Stock Declines
Beam Therapeutics' (BEAM) current chief financial officer, Terry-Ann Burrell, is set to step down from her role on Aug 9. The stock falls 4.7%.
Here's Why You Should Invest in Beam Therapeutics (BEAM) Now
Here, we discuss why investing in Beam Therapeutics (BEAM) stock now may be a prudent move.
Beam Therapeutics (BEAM) Upgraded to Buy: What Does It Mean for the Stock?
Beam Therapeutics (BEAM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
